Translation and validation of European organization for research and treatment of cancer quality of life Questionnaire -C30 into Moroccan version for cancer patients in Morocco

BMC Research Notes

Rachid Bekkali²  Hassan Errihani¹  Abdelatif Benider⁴  Ahmed Zidouh²  Naima Abda³  Karima El Rhazi³  Karima Bendahhou³  Samira El Fakir³  Chakib Nejjari³ 

[1] National Institute of Oncology, Rabat, Morocco;Fondation Lalla Salma Prevention and Treatment of Cancers, Rabat, Morocco;Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco;Oncology Center Ibn Rochd, Casablanca, Morocco

关键词: Validity;    Reliability;    Quality of life;    Cancer;   

Others  :  1133925
DOI  :  10.1186/1756-0500-7-228

 received in 2013-04-23, accepted in 2014-04-02,  发布年份 2014

【 摘 要 】

Background

Understanding the effects of cancer on the quality of life of affected patients is critical to clinical research as well as to optimal management and care. The aim of this study was to adapt the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) questionnaire into Moroccan Arabic and to determine its psychometric properties. After translation, back translation and pretesting of the pre-final version, the translated version was submitted to a committee of professionals composed by oncologists and epidemiologists. The psychometric properties were tested in patients with cancer. Internal consistency was tested using Cronbach’s alpha and the test-retest reliability using interclass correlation coefficients. Construct validity was assessed by examining item-convergent and divergent validity. It was also tested using Spearman’s correlation between QLQ-C30 scales and EQ-5D.

Results

The study was conducted in 125 patients. The Moroccan version was internally reliable, Cronbach’s α was 0.87 for the total scale and ranged from 0.34 to 0.97 for the subscales. The intraclass correlation coefficient of the test-retest reliability ranged from 0.64 for “social functioning” to 0.89 for “physical activities” subscales. The instrument demonstrated a good construct and concomitant validity.

Conclusions

We have developed a semantically equivalent translation with cultural adaptation of EORTC QLQ-C30 questionnaire. The assessment of its measurement properties showed that it is quite reliable and a valid measure of the effect of cancer on the quality of life in Moroccan patients.

【 授权许可】

   
2014 Nejjari et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Redd WH, Montgomery GH, DuHamel KN: Behavioral intervention for cancer treatment side effects. J Natl Cancer Inst 2001, 93(11):810-823.
• [2]Gelber RD, Goldhirsch A, Cavalli F: Quality of life adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 1991, 114(8):621-628.
• [3]Johnson J, Temple R: Food and drug administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985, 69:1155-1159.
• [4]Aaronson NK, Ahmedzai S, Bergman B: The European Organisation for Research and treatment of Cancer QLQ-C30: a quaity of life instrument for use in internetional clinical trials in oncology. J Nat Cancer inst 1993, 85:364-376.
• [5]Guillemin F, Bombardier C, Beaton D: Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993, 46(12):1417-1432.
• [6]Lohr KN, Aaronson NK, Alomso J, Burnam MA, Patrick DL, Perrin EB, Roberts JS: Evaluating quality-of-life and health-status instrument: development of scientific review criteria. Clin Ther 1996, 18:979-992.
• [7]Herdman M, Fox-Rushby J, Badia X: A model of equivalence in the cultural adptation of HRQL instruments: the universalist approach. Qual Life Res 1998, 7:323-335.
• [8]Beaton D, Bombardier C, Guillemin F, Ferraz MB: Guidelines for the process of cross-cultural adaptation of self-report measures. SPINE 2000, 25(24):3186-3191.
• [9]Streiner DL, Norman GR: Health Measurment Scales. Apractical Guide to Their Development and use. Third edition. Oxford: Oxford University Press; 2003.
• [10]Khoudri: 36th Congress of the SRLF. Paris: ; 2008.
• [11]Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al.: The EORTC QLQ-C30 Scoring Manual. 3rd edition. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
• [12]Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16:297-334.
• [13]Aaronson NK, Bullinger M, Ahmedzai S: A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res 1988, 111:231-249.
• [14]Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F: The European Organization of Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in internationl clinical trials in oncology. J Nat Cancer Inst 1993, 85(5):365-376.
• [15]Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S, Ebrahimi M: The European Organization for Research and Treatment of Cancer Qualitu of Life Questionnaire (EORTC QLQ-C30): translation and validation study of the Iranian version. Support Care Cancer 1999, 7(6):400-406.
• [16]Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, You CH, West K: Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004, 13(4):863-868.
• [17]Zhao H, Kanda K: Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res 2000, 9(2):129-137.
• [18]Hoopman R, Muller MJ, Terwee CB, Aaronson NK: Translation and validation of the EORTC QLQ-C30 for use among Turkish and Moroccan ethnic minority cancer patients in the Netherlands. Eur J Cancer 2006, 42:1839-1847.
• [19]Guyatt GH, Feeny DH, Patrick DL: Measurment health-related quality of life. Ann Intern Med 1993, 118:622-629.